Twist Bioscience Corp (TWST)
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Last price
- $173.45
- As of
Kresmion compiles this page from TWST's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Twist Bioscience Corp (TWST): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-19.
See the full TWST dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for TWST on one page. Preview it with sample data, then open it live with a free account.
Preview the TWST dossierActive events for TWST
- mediumEarnings below estimates
Q2-2026: Missed consensus by 11.2%, EPS $-0.56 vs $-0.5036 estimate
- high13F: funds added
5 tracked funds increased TWST this 2026Q2, institutional consensus
- highInsider cluster: sales
4 insiders at TWST sold $16.6M this week
- highInsider cluster: sales
4 insiders at TWST sold $15.8M this week
- high13F: large increase
CITADEL ADVISORS LLC added +137% to TWST (2026Q2)
FREE, NO ACCOUNT
Every event on TWST, as it fires
You are seeing 5 of 18 events recorded on TWST since 2026-06-05.
The five above landed across 5 days. The other 13 were recorded on 3 other days. 9 of the 18 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in TWST (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| D. E. Shaw & Co., Inc.CUSIP 90184D100 · 2026Q2 | $122M | 0.06% | , |
| CITADEL ADVISORS LLCCUSIP 90184D100 · 2026Q2 | $88.7M | 0.01% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 90184D100 · 2026Q2 | $35.7M | 0.01% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 90184D100 · 2026Q2 | $9.7M | 0.01% | , |
| Bridgewater Associates, LPCUSIP 90184D100 · 2026Q2 | $1.9M | 0.01% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, TWST
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
TWST against its peers
TWST's operating margin of -36.2% ranks in the 32nd percentile of 19 Diagnostics & Research sub-industry peers, fiscal periods ending between 2024-12-31 and 2026-06-30.
| Metric | TWST | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 377M USD | 73.4M USD | 74 | 20 |
| Gross margin | 50.7% | 62.2% | 37 | 14 |
| Operating margin | -36.2% | -15.9% | 33 | 19 |
| Net margin | -20.6% | -12.6% | 45 | 20 |
| Return on equity | -16.4% | -7.0% | 36 | 17 |
Peers (22): QGEN, ICLR, BLLN, CDNA, NEO, PSNL, OPK, BDSX, BNR, FONR.D, IMDX, QUCY, PRPO, IDXG, MBAI, MDXH, LDDD, PMDI, XWEL, NDRA, AWHL, ADVB. Left out: ANPCF (no annual filing), BIAF (no annual filing), NOTV.D (no annual filing). Fiscal periods ending between 2024-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (TWST: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow TWST on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to TWST for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.